News
-
Precision immunotherapy for sepsis improves early organ dysfunction, study shows
Researcher Evangelos J. Giamarellos-Bourboulis, MD, PhD, said the conventional wisdom that patients start with hyperinflammation and progress to immunoparalysis is being called into question by the results.
-
Retrospective study confirms RSV, flu significantly increase hospitalization risk in pediatric patients
The study showed that children with comorbidities are at the highest risk, with a fivefold increase in severe outcomes.
-
Rapid RSV testing may reduce antibiotic use in pediatric respiratory infections
Riccardo Boracchini, MSc, said the study provides some of the strongest evidence to date that rapid diagnostic testing can reduce antibiotic use outside the hospital setting.
-
Link between viral pneumonia, lung cancer risk underlies importance of vaccination against respiratory infections
New data add weight to the case for protecting against respiratory viruses as part of lung cancer prevention.
-
Psilocybin-assisted therapy bests nicotine patch for smoking cessation in pilot study
At six months following the target quit date, 40.5% of participants in the psilocybin group achieved biochemically verified prolonged abstinence compared with only 10.0% in the nicotine patch group.
-
Updated sepsis guidelines balance rapid treatment initiation, antibiotic stewardship
In some cases, the new recommendations support treatment initiation before a patient reaches the hospital, while allowing flexibility in other cases to delay treatment until a sepsis diagnosis is confirmed.
-
Small trial shows lower ARDS rate, mortality with sivelestat following cardiopulmonary bypass
Nicholas Villalobos, MD, said that while sivelestat may not represent a single solution for ARDS, evidence that it can temper the inflammatory cascade is positive.
-
Umeclidinium-vilanterol shows modest but consistent advantage among LAMA-LABA options in symptomatic COPD
Investigator William B. Feldman, MD, PhD, MPH, said the findings raise important questions about whether inhalers in the same class are indeed therapeutically equivalent for patients with COPD.
-
Triple therapy shows meaningful benefits in uncontrolled asthma
Alberto Papi, MD, FCCP, said recent data from the KALOS and LOGOS trials suggest triple therapy may address airflow limitation and exacerbation risk in a single inhaler.
-
Phase 3 TETON trials demonstrate positive results for inhaled treprostinil for IPF
Steven D. Nathan, MD, FCCP, said the evidence shows the drug is effective for treating pulmonary hypertension and may slow or prevent fibrosis progression.
